The shortest month of the
year is now over, but the
last week of February
proved to be a long one for
these three horrendous
Ampio Pharmaceuticals (Nasdaq: AMPE)
The stock of the biopharmaceutical firm focusing on antiinflammatory drugs plunged nearly 21% for the week.
Why Ampio tanked
• The company announced a
secondary public offering of 8.5
million shares at $7 per share.
• That amount was well below the
current share price -- leading to the
• Ampio plans to use the added cash in
part to complete clinical trials for
anti-inflammatory drug Ampion and
diabetic macular edema drug Optina.
Questcor Pharmaceuticals (Nasdaq: QCOR)
Shares of the biotech plunged more than 20% this week.
Why Questcor investors were quaking
• A damaging report was published
online by Citron Research.
• Citron alleged that lab results of
samples of Questcor’s primary
drug, Acthar, contained little to none of
its primary active ingredient, ACTH.
• The FDA received Citron’s research and
said the lab findings warrant an
• The allegations overshadowed another
solid earnings performance from
Questcor announced this week.
Aegerion Pharmaceuticals (Nasdaq: AEGR)
The stock of the biopharmaceutical company fell nearly 18% this
Why Aegerion shareholders were agitated
• The company posted a Q4 loss of $0.47
per share -- worse than the expected
• Juxtapid generated $24.5 million in net
product sales for the quarter, but
analysts estimated revenue a tad higher
at $24.9 million.
• Aegerion’s full-year guidance of $190
million to $210 million in net product
revenue was in the expected range but
possibly disappointed investors wanting
Best shot at bouncing back?
• Questcor could very well rebound, but
it’s best to wait for the questions to be
• In my view, Aegerion has a great drug
but needs to generate higher growth to
justify its valuation.
• Ampio’s secondary offering dilutes
available shares by around 8% -- well
below the 21% drop this week.
• Because of this and the potential for its
pipeline drugs, Ampio gets the nod for
the best shot at bouncing back.
Find out which stock The Motley Fool’s chief
investment officer selected as the top pick for
2014 in our free report!